Alto Neuroscience, Ownership
| ANRO Stock | 2.65 0.04 1.49% |
Alto |
Alto Stock Ownership Analysis
About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alto Neuroscience, recorded a loss per share of 2.38. The entity had not issued any dividends in recent years. For more info on Alto Neuroscience, please contact B BCom at 650 200 0412 or go to https://www.altoneuroscience.com.Besides selling stocks to institutional investors, Alto Neuroscience, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Alto Neuroscience,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Alto Neuroscience,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Alto Neuroscience, Quarterly Liabilities And Stockholders Equity |
|
About 8.0% of Alto Neuroscience, are currently held by insiders. Unlike Alto Neuroscience,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Alto Neuroscience,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Alto Neuroscience,'s insider trades
Alto Neuroscience, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alto Neuroscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Etkin Amit over a month ago Acquisition by Etkin Amit of 215000 shares of Alto Neuroscience, at 4.2 subject to Rule 16b-3 | ||
Cox Christopher Nixon over two months ago Acquisition by Cox Christopher Nixon of 25236 shares of Alto Neuroscience, at 4.38 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 10681 shares of Alto Neuroscience, at 12.53 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 2931 shares of Alto Neuroscience, at 13.22 subject to Rule 16b-3 | ||
Alpha Wave Global Lp over a year ago Conversion by Alpha Wave Global Lp of 1962995 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Conversion by Chen Po Yu Jeff of 259 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Acquisition by Chen Po Yu Jeff of 30574 shares of ANRO subject to Rule 16b-3 | ||
Alkeon Capital Management Llc over a year ago ANRO exotic insider transaction detected |
Alto Neuroscience, Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify |
Pair Trading with Alto Neuroscience,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience, will appreciate offsetting losses from the drop in the long position's value.Moving together with Alto Stock
| 0.69 | A | Agilent Technologies | PairCorr |
| 0.67 | EYEN | Eyenovia | PairCorr |
| 0.68 | CGC | Canopy Growth Corp | PairCorr |
| 0.69 | IPA | Immunoprecise Antibodies | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience, to buy it.
The correlation of Alto Neuroscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.